**Name of journal: World Journal of Cardiology**

**ESPS Manuscript NO: 8142**

**Columns: TOPIC HIGHLIGHT**

WJC 6th Anniversary Special Issues (1): Hypertension

Prehypertension: Underlying pathology and therapeutic options

Albarwani S *et al.* Prehypertension: Pathophysiology and treatment

Sulayma Albarwani, Sultan Al-Siyabi, Musbah O Tanira

**Sulayma Albarwani, Sultan Al-Siyabi,** Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman

**Musbah O Tanira,** Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman

**Author contributions:** Albarwani S, Al-Siyabi S and Tanira MT solely contributed to this paper.

**Correspondence to: Musbah O Tanira, Professor,** Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos Universitym, PO Box 35, Muscat 123, Oman. tanira@squ.edu.om

**Telephone:** +968-24-141106 **Fax**: +968-24-141107

**Received:** December 17, 2013  **Revised:** June 8, 2014

**Accepted:** June 14, 2014

**Published online:**

**Abstract**

Prehypertension (PHTN) is a global major health risk that subjects individuals to double the risk of cardiovascular disease (CVD) independent of progression to overt hypertension. Its prevalence rate varies considerably from country to country ranging between 21.9% and 52%. Many hypotheses are proposed to explain the underlying pathophysiology of PHTN. The most notable of these implicate the renin angiotensin system (RAS) and vascular endothelium. However, other processes that involve reactive oxygen species, the inflammatory cytokines prostglandins and C-reactive protein as well as the autonomic and central nervous systems are also suggested. Drugs affecting RAS have been shown to produce beneficial effects in prehypertensives though such was not unequivocal. On the other hand, drugs such as β-adrenoceptor blocking agents were not shown to be useful. Leading clinical guidelines suggest using dietary and lifestyle modifications as a first line interventional strategy to curb the progress of PHTN; however, other clinically respected views call for using drugs. This review provides an overview of the potential pathophysiological processes associated with PHTN, abridges current intervention strategies and suggests investigating the value of using the “Polypill” in prehypertensive subjects to ascertain its potential in delaying (or preventing) CVD associated with raised blood pressure in the presence of other risk factors.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Prehypertension; Renin-angiotensin system; Therapeutic lifestyle changes; Polypill

**Core tip:** There is a current debate over the ideal means of intervening in prehypertension. Since it is the cardiovascular risk that constitute the basis for intervention in both prehypertension and hypertension, the review discusses the following points, that: (1) Categorizing blood pressure levels is based on mere 20 mmHg brackets; hence this doctrine may be re-visited to include other cardiovascular risk factors to categorize patients regardless of their blood pressure level; (2) Investigating the therapeutic potential of intervening in all pathophysiological processes associated with prehypertension; and (3) Ascertaining the therapeutic value of the “Polypill” in prehypertensives as means of primary prevention.

Albarwani S, Al-Siyabi S, Tanira MO. Prehypertension: Underlying pathology and therapeutic options. *World J Cardiol* 2014; In press

**SEARCH AND ARTICLE COLLECTION METHOD**

Initially, PubMed and Scopus were searched using the key words prehypertension, epidemiology, and treatment (as such or in the form of derived terms as appropriate) alone and in combination, were used to identify a set of primary articles. Other searches using pertinent key words were conducted as required; such was particularly utilized during search for pathophysiologically-related publications. For example, treatment + prehypertension led to renin-angiotensin system, which led to angiotensin converting enzyme system, angiotensin converting enzyme inhibitors, angiotensin receptor blockers and so on. To the resulted articles we added our own collection. Reviews were used as another source to include more articles. All searches were limited to English language.

The main aim of this review was to provide an overall understanding of the current status of the medical profession opinion on prehypertension and to map the so far recommended or suggested therapeutic strategies. It also reflected on other potential therapeutic options. The selection of cited references was made to serve that aim.

**CONCEPTUAL OVERVIEW**

***Definitions***

The concept of prehypertension (PHTN) was introduced in 1939 by Robinson and Brucer who were first to draw attention to the range of blood pressure (BP) between 120–139 mmHg (systolic) and 80–89 mmHg (diastolic) as being of value in determining clinically overt HTN[1]. Almost three decades later, the same BP range was given the name “borderline hypertension”[2], then the name changed to “high-normal blood pressure” in 1997[3]. The name “prehypertension” was given in 2003[4]. The nomenclature went further by some authors[5] who categorized BP levels between 130–139/85–89 mmHg (the upper half of PHTN range) as “Stage 2” PHTN. Also the upper half of the HTN range was given the name of “high normal” blood pressure by the European Society of Hypertension/the European Society of Cardiology[6].

Hypertension (HTN) is defined as a systolic/diastolic pressure level of ≥ 140/90 mmHg)[7, **8**]. HTN is a major world health problem and is among the most prevalent chronic conditions with rates that reach up to 70% of adult population in some countries[9] and is on the increase[10]. HTN has been identified as the leading global risk factor for disease burden[11] and it is considered to be the most important modifiable risk factor for coronary heart disease, stroke, congestive heart failure and end-stage renal failure[12].

**SALIENT ISSUES PERTAINING TO BLOOD PRESSURE AND CARDIOVASCULAR RISK**

Prior to start the discussion on the main topic of this review i.e prehypertension, there are a number of issues that are of significant value to this topic and they address the relationship of changes in blood pressure and their correlation with CV morbidity and mortality. These are; the J-blood pressure curve concept; the central versus peripheral blood pressure relation with CV events; and the complex interaction of different antihypertensive drugs on blood pressure and cardiac hemodynamics. A brief account of each of these follows.

***The J-blood pressure curve concept and cardiovascular risk***

The “J-curve” concept describes the shape of the relationship between BP and the risk of CV morbidity or mortality[13]. Some authors considers the J-curve to be more correlated with DBP than SBP[14] since most of coronary blood flow occurs in diastole[15]. Three pathophysiologic mechanisms have been proposed to explain the existence of a J-curve are: (1) low DBP could be an additional risk factor to coexisting or underlying poor health or chronic illness leading to increasing morbidity and mortality; (2) low DBP could be caused by an increased pulse pressure reflecting advanced vascular disease and stiffened large arteries; and (3) over-aggressive antihypertensive treatment could lead to too-low DBP and thus hypo-perfusion of the coronaries resulting in coronary events[13].

The J-curve concept is in line with the thought that BP has a continuous relationship with CV events such as myocardial infarction, stroke, sudden death, heart failure and peripheral artery disease as well as of end-stage renal disease [16-20] even at values such as 110-115 mmHg for systolic blood pressure (SBP) and 70-75mmHg for diastolic blood pressure (DBP)[21-22].

***Central systolic versus peripheral systolic blood pressure and cardiovascular events***

In adults, peripheral systolic blood pressure (pSBP) exceeds central (aortic) systolic blood pressure (cSBP) by about 10 mmHg or more[23] This difference is greater in younger subjects, during exercise and is affected by drug therapy[23]. Because cSBP and central pulse pressure (cPP) are more closely related to the load on the heart and pulsatile stress on the coronary arteries than pSBP, they are suggested to be better predictors of CV events[24, 25]. Additionally, it may be highlighted that the heart, kidneys, and major arteries supplying the brain are exposed to aortic rather than peripheral pressure. Therefore, there is a rationale to believe that CV events may be more related to central rather than brachial pressure[26].

The increase in central pressure from diastolic to systolic values is determined by the compliance of the aorta as well as the ventricular stroke volume. A high central pulse pressure (PP) is considered to be a marker of increased artery stiffness and represents a well-established independent predictor of CV morbidity and mortality[27-29] in hypertensive individuals and even in those considered as having normal BP[30]. PP significantly predicts major adverse CV events including unstable angina pectoris, myocardial infarction, coronary revascularization, stroke, or death[31]. An independent correlation between aortic PP and coronary artery disease was established in men, along with age and hypercholesterolaemia[32,33]. The late decrease in DBP after the age of 60, associated with a continual rise in SBP, is consistent with increased large artery stiffness. Higher SBP, if left untreated, may accelerate large artery stiffness and thus perpetuate a vicious cycle[21].

Indeed, central pressure was found to be more (than peripheral pressure) correlated with indicators such as carotid intima-media thickness[24,-34,35] and left ventricular mass[35-37]. Also, aortic pulse pressure was found to be significantly and independently correlated with angiographically determined coronary artery stenosis[38] and more related to CV events than brachial pressure[24, 39-41] and responds differently to certain drugs[25,42]. For example, it was found that the Beta-blocker, atenolol, is inferior to other major anti-hypertensive drug classes in preventing CV events. Beta-blockers exert differential effects on brachial *vs* central pressure which may help to explain the adverse findings with atenolol in outcome studies and provides support for the hypothesis that drugs which lower central pressure the most will be more effective[43-48]

***Antihypertensive drugs and cardiovascular events***

The interaction of antihypertensive drugs on BP and coronary hemodynamics (and hence CV events) is complex. For example not all antihypertensive drugs have similar effects on pulse pressure. Blockers of the renin angiotensin system, calcium antagonists and diuretics improve arterial compliance and thus lower SBP more than DBP and therefore diminish pulse pressure. In contrast beta-blockers, because they decrease heart rate, increase stroke volume would have a less favorable effect on pulse pressure than the other drugs. Yet, decreased heart rate may allow for more prolonged diastolic perfusion of the coronary vascular bed and *vice versa*; whereas, short-acting calcium antagonists and other arteriolar vasodilators (such as hydralazine, minoxidil) are prone to cause myocardial ischemia in susceptible patients[49].

Antihypertensive drugs that reduce LVH and hypertensive vascular disease are more effective over the long term in improving coronary flow reserve than drugs that have little or no effect. Thus, blockers of the renin angiotensin system, calcium antagonists as well as the diuretics, have been shown to reduce LV hypertension[50] and hypertensive vascular disease[51-53] and improve arterial compliance[57] better than beta-blockers.

**EPIDEMIOLOGY OF PHTN**

Many studies in various countries were performed to determine the magnitude of the PHTN rate. These have revealed that PHTN prevalence is considerable and it varies widely from country to country. For example, prevalence rate averages at 21.9% in China[55], at 32.8% in the Netherlands[56], at 34% in Taiwan[57], at 37% in the United States[58], at 40% in Ghana[59], at 48.2% in Oman[60] and at 52% in Iran[61]. Men[57-59, 61] and blacks[62] are more likely to be affected than women or whites; respectively.

**CARDIOVASCULAR RISK OF PHTN**

PHTN is not only a caveat to develop overt HTN, but it is a major health risk on its own also. Prehypertensives were repeatedly reported to be subjected to approximately double the risk of cardiovascular disease (CVD) independent of progression to HTN[58,63] in addition to other cardiovascular complications[55,64].

**PATHOPHYSIOLOGIC CHANGES ASSOCIATED WITH RAISED BP**

This part of the review is intended to discuss briefly the significant pathophysiologic changes associated with the progressive increase in BP to provide the scientific premise for currently recommended interventions or another that is recommended by this review.

**INVOLVEMENT OF THE RENIN-ANGIOTENSIN SYSTEM**

***Effects of RAS on cardiovascular system in general***

Angiotensin II, an active peptide of the renin–angiotensin system (RAS), causes increase in BP and enhances oxidation of the low-density lipoprotein *via* stimulation of its type 1 receptor (AT1)[67,68]. It appears that it acts in this respect by inhibiting NAD(P)H oxidase-mediated oxygen synthesis and enhances antioxidant superoxide dismutase activity in the cardiovascular system and decreases nitric oxide (NO) bioavailability. The latter effect may be responsible, at least in part, for the beneficial effects of drugs inhibit RAS activity such as angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs) that may act, eventually, by enhancing NO availability[69-71]. However, RAS blockade provides additional protective effect on cardiovascular function that cannot be solely explained by mere reduction of BP which is the action mediated by increasing NO availability[72].

In this context, it may be added that angiotensin-converting enzyme 2 (ACE2) converts angiotensin I to angiotensin (Ang)-1-9, that can be converted by ACE to a shorter peptide, Ang-1-7, which has an intrinsic vasodilator activity[73,74]. ACE2 have been described to be a potent negative regulator of RAS, counterbalancing the multiple functions of ACE, thus, it plays a protective role in the CV system and other organs[75].

Also, chronic activation of the RAS was shown to underlie HTN, insulin resistance, cardiac and renal disease, and polycystic ovarian syndrome and it serves as a link between obesity and low-grade systematic inflammation[76-80]. In addition, it is suggested that RAS contributes to the atherosclerotic process through angiotensin II which acts as a proinflamatory mediator directly inducing atherosclerotic plaque development and heart remodeling and exacerbate endothelial dysfunction[81,82]. On the other hand, blockade of RAS can offer protection from RAS-related metabolic diseases including diabetes[83-88].

The statement by Demirci *et al*[72] is further enforced by the observation that the ACE gene may be a determinant of serum ACE levels, but it does not appear to confer susceptibility to essential hypertension[89], since there are many factors that influence the genetic make-up of blood pressure[90]. In addition, other environmental factors[91] may be involved in determining BP. Therefore, the possibility of drugs interfering in the RAS to be additionally interfering with any of these other factors cannot be eliminated.

***Effect of RAS on development of hypertension***

The first report on the potential of early intervention to prevent HTN was in 1990[92]. The authors showed that inhibiting RAS by captopril (an ACEI) for two weeks may intervene in the progression of HTN in young “prehypertensive” spontaneously hypertensive rats (SHRs). Later, other studies have shown that transient inhibition of the renin-angiotensin system from two weeks of age in SHRs, either with ACEIs or with ARBs, diminishes the increase in BP for up to 21 wk after cessation of treatment[93]. While others reported that permanent treatment of SHRs from conception onwards with ACEIs completely prevents hypertension[94, 95].

The ARBs losartan was reported to have beneficial effect in humans[96] and rats[97,98] similar to that of captopril in SHRs, specifically, as shown by another study that transient use of losartan resulted in a long-lasting improvement of arterial contractility an effect that was linked to endothelium-dependent vasodilatation[92, 98].

Paradoxically, other authors showed that decreased BP is accompanied by severe disruption of the normal vascular architecture of intrarenal arteries[99]. These authors concluded that, apparently interference with RAS during a crucial stage of development in SHRs can initiate this disturbance and may cause intrarenal vascular smooth muscle hyperplasia, suggesting the involvement of another trophic factor that is inhibited by angiotensin II under physiologic conditions. Such led other workers[72] to suggest that the efficacy of antihypertensive treatment is also influenced by age and the hypertensive stage of the animals.

**INVOLVEMENT OF VASCULAR ENDOTHELIUM**

The association between RAS and endothelium-dependent pathways in PHTN was suggested by more than one observation. It was shown that dysfunctional NO synthesis in PHTN may be a source of oxygen free radicals or reactive oxygen species (ROS) which may be an additive factor to develop overt HTN[104]. Jameson *et al*[101] reported that, endothelium-dependent relaxation of prehypertensive SHRs mesenteric arteries was impaired. Later, interleukin-1 β (which induces inducible NO Synthase) was shown to cause a lower production of NO and a reduced generation of cGMP in these animals[102]. This observation was followed by demonstrating that lower NO level correlated with increased systolic BP in the same species[103]. Such was related to impaired NO production alone[104] or combined with an enhanced ROS activity which may contribute to progression of PHTN to HTN[105]. All these effects indicate that endothelial vasodilator capacity is impaired in PHTN[106].

**INVOLVEMENT OF REACTIVE OXYGEN SPECIES (ROS)**

It is stated above that ROS may add to developing overt HTN. Therefore, it is not surprising that antioxidant deficiency has been long implicated in HTN pathogenesis[107-109]; whereas, antioxidant treatment to reduce oxidative stress was shown to prevent development of HTN in SHRs[110]. Many studies have demonstrated that enhanced production of plasma free radicals may impair the physiologic function of vascular endothelium[111-113]. An action that may lead to increase in BP. Recently, the rationale for antioxidant trials in PHTN was reviewed by Nambiar *et al*[114].

**INVOLVEMENT OF THE INFLAMMATORY PROCESS: PROSTGLANDINS AND C-REACTIVE PROTEIN**

Inflammation was also implicated in the development of HTN and in endothelial dysfunction either as a primary or a secondary event[115]. Inflammation, indicated by C-reactive protein (C-RP) level, was used to predict HTN among PHTN subjects[116, 117]. In addition, prostaglandin E2 (an inflammatory cytokine) was particularly shown to enhance norepinephrine-pressor response in PHTN; an effect that was abolished by indomethacin (a prostaglandin synthesis inhibitor)[118].

**INVOLVEMENT OF THE AUTONOMIC NERVOUS SYSTEM**

*Eyal et al*[119] suggested that α-adrenoceptors of SHRs are in a basic state of excitation even prior to the onset of overt HTN i.e. in PHTN. Prior to this observation, Fujimoto *et al*[120] demonstrated that β-adrenoceptor-mediated relaxation of arteries, in same species, was diminished before and during development of HTN. The diminished relaxation may be because of defective hyperpolarisation induced by these receptors[121]. In the same rat species, both the M3 cholinoceptors- and P2y-mediated relaxation was not altered[122] ruling out involvement of any other component of the autonomic nervous system apart from the sympathetic. However, β-blockers, compared to ACEIs, did not improve resistance arteries function after two years of use in human[123,124].

The underlying mechanism for the sympathetic involvement was also indicated by the presence of sub-sensitive presynaptic α2-adrenceptors which may lead to exaggerated norepinephrine secretion[125], an effect that may have a causal relevance to development of HTN[126]. Similarly, the β2-adrenceptor-mediated facilitation of neurogenic pressor response was found to be enhanced in prehypertensive SHRs, which may contribute to development of HTN[127].

**INVOLVEMENT OF CENTRAL MECHANISMS**

An impaired baroreceptor control of vascular resistance was implicated in SHRs[128] and such was thought to be a primary defect[129]. In humans, baroreflex was not found to be altered, but plasma norepinephrine positively correlated to BP and associated with subsensitive α- and β-adrenoceptors[130].

Another explanation of the symapthetic overactive state in PHTN/HTN was postulated by Kotchen *et al*[131]. It is based on the observation that brain NO, as a neurotransmitter, reduces sympathetic output, and systemic angiotensin II activates NO-producing neurons. SHRs show higher gene expression of nNOS, probably, as a compensatory mechanism for increased BP. That hypothesis was supported by the finding that hypothalamic angiotensin II-sensitive neurons activity was greatly enhanced in PHTN[132], and that the central component of the baroreflex was also impaired[133].

**INVOLVEMENT OF OTHER MECHANISMS**

Other than RAS pathways should be investigated since not all the beneficial effects attributed to anti-RAS drugs (in HTN and PHTN) can be solely understandable by its mere reduction in BP. For example, RAS is activated by common comorbidity including Type 2 diabetes, hyperinsulinemia and excess weight as well as it can be activated by a diet rich in carbohydrates and fats. Two clinical trials[134, 135] have shown that ACEIs decrease the risk of developing Type 2 diabetes in patients with HYN and/or vascular disease.

**THERAPEUTIC OPTIONS OF PREHYPERTENSION**

***Rationale for therapeutic intervention in phtn***

PHTN and HTN are associated with a number of factors such as increased age, male gender, increased C-RP level and waist circumference[117, 136]. These factors are positively correlated with the development of HTN[117]. Yet and despite the clear relationship between HTN and PHTN, treating HTN is unequivocally accepted, but the debate over the use of the term PHTN itself as a clinical category[137] or what type of intervention to be used in this case has not yet been concluded. The main reasons raising the thought of therapeutically intervening in prehypertensive subjects can be summarized as follows: (1) Elevated systolic BP is the most important risk factor for cardiovascular, cerebrovascular, and renal disease[4, 16 ,138]; (2) There is a strong association of cardiovascular mortality risk with BP[16]; (3) It is expected that many individuals with PHTN will, with time, become overt hypertensive patients[139]; and (4) For normotensive population, it was calculated that systolic BP increases at an average rate of about 0.5 mmHg/year[137].

***Current suggested intervention strategies in PHTN***

In principle, intervening in PHTN is a form of primary prevention, which can be enacted in more than one way. One is by the use of proven and safe drugs; another is by inducing individual behavioral changes. The latter is an attractive option because of its inherent “natural” appeal, perceived low cost, simplicity and safety though may not be sustainable.

Primary prevention strategies that are directed towards the individual necessitate screening all individuals in order to identify those who are over a certain “threshold”. That process is followed by subjecting individuals at risk to an appropriately “tailored” intervention to each of them which incurs high cost. In addition, risk prediction in primary prevention remains imprecise and may not reflect long-term risk[140].

At the community level, primary prevention may be endorsed by passing health policies, encouraging beneficial cultural attitudes and/or imposing environmental changes. This approach is more likely to have a greater impact on individual’s health[141-144].

At present, it is agreed in principle, that prehypertensive subjects should be treated. However, there is a polarizing controversy on the means of intervention. Two main strategies are recommended; one is based on “Therapeutic Life Changes (TLCS)”[4], and the second is based on using antihypertensive monodrug therapy[5].

**THERAPEUTIC LIFESTYLE CHANGES (TLCS)**

Previous[3] and current guidelines[5] advocate specific lifestyle modifications for prehypertensives. The most recent recommendations (JNC7 report)[4] are as follows: (1) Maintain body mass index between 18.5 and 24.9 kg/m2; this is expected to reduce systolic BP by 5 to 20 mmHg for each 10-kg reduction in weight; (2) Consume a diet rich in fruits and vegetables, as well as low-fat dairy products; this is expected to reduce SBP by 8 to 14mmHg; (3) Restrict sodium to no more than 6 g of table salt per day; this is expected to reduce SBP by 2 to 8 mmHg; (4) Walk briskly at least 30 min per day or engage in other regular aerobic physical activity; this is expected to reduce SBP by 4 to 9 mmHg; and (5) Reduce alcohol consumption; this reduces SBP by 2 to 4 mmHg.

***Evidence for therapeutic effectiveness of lifestyle modifications***

The JNC 7 lifestyle changes are focused on weight loss, dietary restriction and exercise, which were supported by abundant clinical evidence. For example, weight loss[145], and salt restriction[146] have been shown to improve PHTN. Maintaining a body mass index between 18.5 and 24.9 kg/m2 is expected to reduce systolic BP by 5 to 20 mmHg for each 10-kg reduction in weight[16].

Weight loss has been shown to be the most effective lifestyle modification strategy for prevention of hypertension[147]. Reductions in BP occur even without attainment of normal body mass index. In a meta-analysis of 25 randomized, controlled trials, weight loss of 1 kg was associated with approximately 1 mmHg reduction in SBP and DBP in individuals with HTN[148]. Addition of antihypertensive medication has been shown to have an effect on BP reduction that is additive to that achieved by weight loss alone[148, 149]. However, it has been shown that the type of medication prescribed may decrease the ability of the patient to lose weight[147].

Dietary pattern changes, in general[150] or specifically prescribed such as the Dietary Approaches to Stop Hypertension (DASH) plan[151, 152] which uses a diet rich in fruits, vegetables, legumes, nuts, and low-fat dietary products and low in saturated fats, induced a significant lowering of BP. Adhering to the DASH diet can reduce BP by 8–14 mmHg, an effect that was augmented even further when dietary sodium was restricted. The OmniHeart Collaborative Research Group study[154] in which the DASH diet was modified to provide more protein and unsaturated fat and less carbohydrate, impressive reductions of BP were also achieved. The TOHP trial[147], in a substudy of the DASH trial also showed that by reducing sodium intake to less than 100 mmol in your daily diet, in addition to dietary changes provided greater benefit than either approach alone[153].

Similarly, there is ample evidence that exercise, independent of weight loss, decreases BP[154-157]. A number of clinical trials demonstrated that increased physical activity can lower BP independent of any effect on body weight, although this finding is not universal[158-160]. However, two meta-analyses concluded clearly that physical activity independently lowers BP[161, 162]. In one of these meta-analyses, 27 of 50 studies reported results in nonhypertensive subgroups, which presumably include a large proportion of participants with PHTN[162]. Exercise alone has been associated with a 30% reduction in cardiac risk, making it similar to statin and antihypertensive interventions[163-166]. Hence, a number of studies have been performed to examine the effects of aerobic and/or resistance exercise on BP in hypertensive, prehypertensive, and normotensive groups, and a recent review has examined the relevant findings[167].

Nevertheless, some trials have shown that LCTs to have a modest and unsustainable impact to reduce CVD events when tested in large, long-term trials[152, 168]. This observation has been challenged by the PREMIER trial[169] which studied the combined effects of diet, physical activity, and weight reduction in three groups of prehypertensive and hypertensive subjects over an 18-month period. Although all three groups demonstrated significant reductions in BP in both prehypertensive and hypertensive subjects, the amount of decrease in the group given relatively minimal counseling was both surprising and gratifying in view of the previous difficulties with obtaining long-term behavioural changes to improve the cardiovascular risk status. These findings encourage adding counseling as an important early augmenting intervention to lifestyle modifications that may sustain beneficial therapeutic effect. This view is further supported with the findings of the largest population-based experience of lifestyle modification as a strategy to reduce cardiovascular risk factors, CVD, and mortality. The study used a comprehensive community-level approach that encompassed the health and other services like voluntary organizations, local media, businesses including the Food Industry and changes to public policy. It demonstrated a reduction in mortality from coronary artery disease by 55% in men and by 68% in women over a 20 year period[170]. Furthermore, in a recent randomized clinical trial[171] it was found that subjects with increased BP who participated in an automated online self-management program resulted in improved BP among prehypertensive or hypertensive subjects. These findings emphasize the need to involve patients for a more sustainable outcome. Similar results were obtained in overt hypertensive patients, who, in a prospective cohort study received repeated nonpharmacological recommendations to follow low-salt and low-calorie diets and to do physical activities[172]. This study concluded that adherence to follow low-salt and low-calorie diets is associated with clinically relevant long-term BP reduction and better hypertension control in clinical setting.

Although the evidence on reducing alcohol intake and reduction in BP equivocal[173, 174], a meta-analysis of trials in this respect with many of the analysed trials included prehypertensives[175] suggest that reducing alcohol intake can independently lower systolic BP.

**THERAPEUTIC INTERVENTION WITH A MONODRUG THERAPY**

All concluded studies that have been attempting to treat PHTN used one drug that affects the RAS in the form of ACEIs, ARBs or renin inhibitors. The use of other monotherapies such as β-blockers, was not shown to be, compared to ACEIs, effective in improving resistance arteries function after two years of use in human[123, 124]. The involvement of RAS in PHTN and HTN was discussed earlier. This part of the review summarizes the outcome of clinical trials using drugs that affect RAS.

***Clinical trials with drugs affecting ras: ongoing clinical trials***

Two clinical trials are ongoing: (1) The first trial is the PREVER-Prevention trial[176], a controlled randomized, double-blind trial designed to include individuals with PHTN given chlorthalidone 12.5 mg plus amiloride 2.5 mg or placebo. The study is to investigate if early use of drugs in individuals with PHTN may prevent cardiovascular events, target-organ damage and the incidence of overt HTN. In the 2nd International Conference on Prehypertension and Cardiometabolic Syndrome (January 31 - February 3, 2013; Barcelona, Spain) the trial co-principal investigator (Fuchs FD) announced that PREVER has finished enrollment of 1053 patients. According to the study design, patients who are still prehypertensive after three months of recommended lifestyle changes are randomized to a low-dose combination of chlorthalidone plus amiloride or to placebo. Preliminary results from the study[177] indicate that 659 (77%) of subjects remained prehypertensive and were randomized according to the study protocol; another 7.5% had abnormal lab values, and 6.2% had progressed to developing HTN, while 9% had seen their BP drop to within normal values; and (2) The second trial is the Chinese High Normal Blood Pressure (CHINOM) trial. The study has finished enrollment of 10689 patients with BP in the range of 130–139/85–89 mm Hg and at least one other cardiovascular disease risk factor (but no established diabetes, renal or hepatic dysfunction, or history of stroke or CVD. The trial randomized patients to one of three parallel treatment groups: telmisartan 40 mg, indapamide 1.5 mg, or, in the third group, placebo or a combination pill of hydrochlorothiazide 12.5 mg, triamterene 12.5 mg, dihydralazine 12.5 mg, and reserpine 0.1 mg. The primary end point of the study is combined CV events (nonfatal stroke, nonfatal MI, and CVD death), while secondary end point addresses new-onset hypertension and new-onset diabetes. In the above mentioned conference, it was announced that the CHINOM trialis still awaiting the first results which may be still several years away. However, baseline characteristics of study subjects are showing that 70% of subjects enrolled actually have more than one cardiovascular risk factor with metabolic syndrome being the most common. More than three-quarters of participants are overweight or obese, 42% have high triglycerides, and over one-third have a family history of hypertension[177].

***Clinical trials with drugs affecting RAS: concluded clinical trials***

The first clinical trial was the TRial Of Preventing HYpertension (TROPHY)[178, 179] which examined whether early treatment of PHTN justified pharmacologic intervention with the use of an ARB (candesartan 16 mg daily) in HTN. TROPHY hypothesis to examine whether ARBs may be useful to treat PHTN was based on the following: (1) PHTN is a strong independent predictor of cardiovascular events; (2) Growth factors mediated by stimulation of the sympathetic nervous system[180] and excess activity of RAS[181] tend to promote vascular hypertrophy by direct as well as hemodynamic effects. Antihypertension treatment with ACIs or ARBs, but not with betablockers, has been reported to cause regression of arteriolar hypertrophy[123, 124]; and and (3) Despite intensive community efforts to promote healthy lifestyle, the prevalence of PHTN[182] in the United States is increasing.

Over a period of four years of TROPHY study, it was found that stage 1 HTN developed in nearly two thirds of patients with untreated PHTN (the placebo group). Treatment of PHTN with candesartan appeared to be well tolerated and reduced the risk of incident HTN during the study period. The authors concluded that, treatment of PHTN appears to be feasible.

Although the observations in this study indicate that candesartan may ameliorate BP in prehypertensives, a comment by the authors stated that they do not advocate treatment of the 25 million people(in the United States) with prehypertension. They added that additional studies will be needed to ascertain whether this or other strategies involving early pharmacologic treatment of prehypertension would positively affect clinical outcomes.

Another trial is the PHARAO study[183] which demonstrated that ramipril (an ACEI) given to prehypertensives reduced the risk of HTN by 34.4% compared to those not taking antihypertensive drugs; however, no differences were found in cardiovascular or cerebrovascular events. The study concluded that prehypertensives are more likely to progress to overt HTN than those with optimal or normal BP when treated with ACEIs.

A third trial, on the other hand, concluded that pharmacological therapy is indicated for some patients with PHTN who have specific comorbidities, including diabetes mellitus, chronic kidney disease and coronary artery disease[184], while another trial[185] did not support the use of antihypertensive drugs in “normotensive” subjects and that, ARBs might offer less protection against myocardial infarction than ACEs.

Most recently, the AQUARIUS trial[186] examined the effect of aliskiren (a renin inhibitor) on progression of coronary atherosclerosis in a double-blind, randomized, multicenter trial study. It concluded that among participants with PHTN and coronary artery disease, the use of aliskiren compared with placebo did not result in improvement or slowing of progression of coronary atherosclerosis and that their findings do not support the use of aliskiren for regression or prevention of progression of coronary atherosclerosis.

**INTERVENTION WITH MULTIDRUG FORMULATIONS: SHOULD THE “POLYPILL” BE CONSIDERED IN PHTN?**

***What is the “Polypill”?***

The “Polypill” is a multidrug formulation with modified drug combinations containing drugs such aspirin, statins, β-blockers, ACEIs and ARBs; all of which are of proven value in reducing CVD morbidity and mortality. Approximately, half of the decline in cardiovascular mortality observed in developed countries during the last two decades is attributable to medical therapy using these types of drugs[187].

The introduction of the Polypill idea was not intended for use in PHTN, rather it was for reducing the burden of CVD in economically disadvantaged individuals to reduce cost and improve adherence. It was meant to be applied to entire or large segments of the population. The reasons behind innovating the Polypill (see below) were, in effect, the same as those for intervening with PHTN, the authors suggest considering to include prehypertensives in future Polypill clinical trials to ascertain the potential benefit of using the Polypill in these subjects.

***Rationale behind the polypill composition***

Some of the main relevant reasons for introducing the Polypill are summarized as follows: (1) Cardiovascular disease is the major cause of death and disability globally and affects approximately half of all individuals over their lifetimes[140]. CVD has increased in developing countries, and by the year 2020, 80% of the global CVD mortality is predicted to occur in low- and middle-income countries[188]; (2) World population is threatened by increasing obesity, sedentary lifestyles, and diabetes mellitus rates[187]. If these conditions are added to increased BP, primary intervention strategies directed towards community rather than individuals become of more therapeutic value; (3) Nine to ten potentially modifiable risk factors account for 90% of the attributable risk for myocardial infarction and stroke, with similar estimates in all major regions of the world[189, 190]; and (4) The prevalence of low risk factor burden is on the increase. In the US it was only 4.4% during 1971–1975, 10.5% during 1988–1994, and 7.5% during 1999–2004[191].

In addition to the above reasons, it has been shown that monodrug therapeutic intervention in PHTN has yielded mixed results, with some researchers have shown benefits[184] while others have not[185]. It seems that the existence of comorbidities determines how a prehypertensive subject is likely to respond to pharmacological intervention[192]. Hence, the authors propose to consider including prehypertensives in future clinical trial of the Polypill to investigate how much benefit they may gain by multidrug therapeutic intervention.

***Clinical evidence for the polypill effectiveness***

Two randomized, placebo-controlled trials investigated the therapeutic effect of the polypill. The first was conducted in 2011**[**193]. It was an international randomised placebo-controlled trial of a four-component combination pill ("polypill'') in people with raised cardiovascular risk (over 7.5%, determined by the Framingham risk) using data on age, gender, BP, total cholesterol, HDL cholesterol, diabetes status, and cigarette smoking status. It contained aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg, and simvastatin 20 mg or to placebo. The drug combination was associated with a 9.9-mm-Hg drop in systolic BP and a 0.8-mmol/L reduction in LDL cholesterol over a 12-week treatment period.

The second clinical trial[194] studied a polypill contained amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg and simvastatin 40 mg.; but contained no aspirin. The pill was given for 12 wk. The treatment showed reductions mean systolic (17.9 mm Hg) and diastolic BP (9.8 mm Hg) and LDL blood level was reduced by 1.4 mmol/L.

**CONCLUSION**

PHTN is a major health challenge that requires extra-attention. The “challenge” resides in finding the answer to “how/what” should be the intervention strategy (or strategies) that may best reduce its health impact.

In the search for a “strategy” to intervene in prehypertension, a number of considerations may be noteworthy and can be summarized as follows: (1) The rationale behind therapeutic intervention in hypertensive, and, indeed, prehypertensive subjects is to prevent (or delay progression of) cardiovascular events and mortality caused by these conditions. Yet, it is equally accepted that presence of other comorbidities such as diabetes mellitus, obesity, dyslipidemia etc. in addition to ethnic, age and gender differences should also be accounted for when an intervention strategy considered; (2) The term PHTN is based on “defining” HTN itself, which is established on a 20-mmHg per brackets. Yet, BP is confounded by many factors such as circadian rhythms, food intake, stress, exercise, emotional state etc. leading to “variable BP variability”[137, 195]; (3) Based on the above two points, it is plausible to suggest that, categorizing and staging of subjects on basis of BP alone may need to be re-considered. It may be more clinically useful to contain factors, together, that cause BP variability to “stage” BP levels as well as to calculate cardiovascular risk factors. Such, may produce new terminologies or new definitions of PHTN and HTN. Consequently, an intervention strategy may not be “one-size-fits-all”, and may necessitate more than one intervention. Different strategies (or combination thereof) may be considered. For example, males may require a different strategy from females since differences between genders have been reported in overt HTN[196, 197]. Similarly, children PB progression differs from that of adults[198] and, thus may need a different intervention strategy. Furthermore, different ethnicities have shown different patterns in both progression of their BP as well as response to therapy and, hence, they may need different intervention strategies[199-202]; (4) The first-line treatment for prehypertensives should be based on adoption of a healthy lifestyle, especially if there are other associated risk factors such as obesity, dyslipidemia, pre-diabetes or diabetes, excessive alcohol intake, sedentary lifestyle and smoking[203] as well as salt-intake restriction[152]. It is desirable if TLCs would be adopted by government and NGOs and may be “enforced” as a “policy” that is directed (in a way similar to the antismoking campaign) towards changing community behavior; and (5) If pharmacologic means will be used, such should not be confined to drugs affecting RAS, other drugs may be investigated to ascertain whether it is the mere reduction in BP that is benefitting prehypertensives or other effects.

**REFERENCES**

1 **Robinson SC,** Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. *Arch Int Med* 1939; **64**: 409–444 [DOI: 10.1001/archinte.1939.00190030002001]

2 **Julius S**, Schork MA. Borderline hypertension--a critical review. *J Chronic Dis* 1971; **23**: 723-754 [PMID: 4933751 DOI: 10.1016/0021-9681(71)90005-1]

3 . The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997; **157**: 2413-2446 [PMID: 9385294]

4 **Chobanian AV**, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560-2572 [PMID: 12748199 DOI: 10.1001/jama.289.19.2560]

5 **Egan BM**, Nesbitt SD, Julius S. Prehypertension: should we be treating with pharmacologic therapy? *Ther Adv Cardiovasc Dis* 2008; **2**: 305-314 [PMID: 19124429 DOI: 10.1177/1753944708094226]

6 **Mancia G**, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2013; **34**: 2159-2219 [PMID: 23771844]

7 **Carretero OA**, Oparil S. Essential hypertension. Part I: definition and etiology. *Circulation* 2000; **101**: 329-335 [PMID: 10645931 DOI: 10.1161/01.CIR.101.3.329]

8 **Liebson PR**. CHARISMA and TROPHY. *Prev Cardiol* 2006; **9**: 235-238 [PMID: 17085987 DOI: 10.1111/j.1520-037X.2006.04994.x]

9 **Kearney PM**, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. *J Hypertens* 2004; **22**: 11-19 [PMID: 15106785 DOI: 10.1097/00004872-200401000-00003]

10 **Flynn JT**. Hypertension in the young: epidemiology, sequelae and therapy. *Nephrol Dial Transplant* 2009; **24**: 370-375 [PMID: 18996836 DOI: 10.1093/ndt/gfn597]

11 **Ezzati M**, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. *Lancet* 2002; **360**: 1347-1360 [PMID: 12423980 DOI: 10.1016/S0140-6736(02)11403-6]

12 **He J**, Whelton PK. Epidemiology and prevention of hypertension. *Med Clin North Am* 1997; **81**: 1077-1097 [PMID: 9308599 DOI: 10.1016/S0025-7125(05)70568-X]

13 **Messerli FH**, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? *J Am Coll Cardiol* 2009; **54**: 1827-1834 [PMID: 19892233 DOI: 10.1016/j.jacc.2009.05.073]

14 **Farnett L**, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? *JAMA* 1991; **265**: 489-495 [PMID: 1824642 DOI: 10.1001/jama.265.4.489]

15 **Morita K**, Mori H, Tsujioka K, Kimura A, Ogasawara Y, Goto M, Hiramatsu O, Kajiya F, Feigl EO. Alpha-adrenergic vasoconstriction reduces systolic retrograde coronary blood flow. *Am J Physiol* 1997; **273**: H2746-H2755 [PMID: 9435611 DOI: ]

16 **Lewington S**, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903-1913 [PMID: 12493255 DOI: 10.1016/S0140-6736(02)11911-8]

17 **Britton KA**, Gaziano JM, Djoussé L. Normal systolic blood pressure and risk of heart failure in US male physicians. *Eur J Heart Fail* 2009; **11**: 1129-1134 [PMID: 19861382 DOI: 10.1093/eurjhf/hfp141]

18 **Kalaitzidis RG**, Bakris GL. Prehypertension: is it relevant for nephrologists? *Kidney Int* 2010; **77**: 194-200 [PMID: 19924105 DOI: 10.1038/ki.2009.439]

19 **Lawes CM**, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; **21**: 707-716 [PMID: 12658016 DOI: 10.1097/00004872-200304000-00013]

20 **Brown DW**, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. *Am J Hypertens* 2007; **20**: 338-341 [PMID: 17324749 DOI: 10.1016/j.amjhyper.2006.08.004]

21 **Franklin SS**, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. *Circulation* 1997; **96**: 308-315 [PMID: 9236450 DOI: 10.1161/01.CIR.96.1.308]

22 **Vishram JK**, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T, Broda G, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Sans S, Olsen MH. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. *Hypertension* 2012; **60**: 1117-1123 [PMID: 23006731 DOI: 10.1161/HYPERTENSIONAHA.112.201400]

23 **Nichols WW**, O'Rourke MF. McDonald's blood flow in arteries. Theoretical, experimental and clinical principles. London: Arnold, 1998. [ISBN-13: 978-0340985014]

24 **Roman MJ**, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension* 2007; **50**: 197-203 [PMID: 17485598 DOI: 10.1161/HYPERTENSIONAHA.107.089078]

25 **Williams B**, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006; **113**: 1213-1225 [PMID: 16476843 DOI: 10.1161/CIRCULATIONAHA.105.595496]

26 . Central blood pressure: current evidence and clinical importance. *Eur Heart J* 2014; : [PMID: 24459197 DOI: 10.1093/eurheartj/eht565]

27 **Benetos A**, Zureik M, Morcet J, Thomas F, Bean K, Safar M, Ducimetière P, Guize L. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. *J Am Coll Cardiol* 2000; **35**: 673-680 [PMID: 10716470 DOI: 10.1016/S0735-1097(99)00586-0]

28 **Domanski MJ**, Sutton-Tyrrell K, Mitchell GF, Faxon DP, Pitt B, Sopko G. Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization. The Balloon Angioplasty Revascularization Investigation (BARI). *Am J Cardiol* 2001; **87**: 675-679 [PMID: 11249882 DOI: 10.1016/S0002-9149(00)01482-X]

29 **Domanski M**, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA* 2002; **287**: 2677-2683 [PMID: 12020303 DOI: 10.1001/jama.287.20.2677]

30 **Benetos A**, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. *Hypertension* 1998; **32**: 560-564 [PMID: 9740626 DOI: 10.1161/01.HYP.32.3.560]

31 **Chirinos JA**, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, Perez G, Mendez AJ. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. *Hypertension* 2005; **45**: 980-985 [PMID: 15837821 DOI: 10.1161/01.HYP.0000165025.16381.44]

32 **Danchin N**, Benetos A, Lopez-Sublet M, Demicheli T, Safar M, Mourad JJ. Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study. *Am J Hypertens* 2004; **17**: 129-133 [PMID: 14751654 DOI: 10.1016/j.amjhyper.2003.09.010]

33 **Pařenica J**, Kala P, Jarkovský J, Poloczek M, Boček O, Jeřábek P, Neugebauer P, Vytiska M, Pařenicová I, Tomčíková D, Pávková Goldbergová M, Spinar J. Relationship between high aortic pulse pressure and extension of coronary atherosclerosis in males. *Physiol Res* 2011; **60**: 47-53 [PMID: 20945964]

34 **Boutouyrie P**, Bussy C, Lacolley P, Girerd X, Laloux B, Laurent S. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. *Circulation* 1999; **100**: 1387-1393 [PMID: 10500038 DOI: 10.1161/01.CIR.100.13.1387]

35 **Wang KL**, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? *J Hypertens* 2009; **27**: 461-467 [PMID: 19330899 DOI: 10.1097/HJH.0b013e3283220ea4]

36 **Roman MJ**, Okin PM, Kizer JR, Lee ET, Howard BV, Devereux RB. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. *J Hypertens* 2010; **28**: 384-388 [PMID: 20051906 DOI: 10.1097/HJH.0b013e328333d228]

37 **Covic A**, Goldsmith DJ, Panaghiu L, Covic M, Sedor J. Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. *Kidney Int* 2000; **57**: 2634-2643 [PMID: 10844634 DOI: 10.1046/j.1523-1755.2000.00124.x]

38 **Ozaki M**, Masuoka H, Kawasaki A, Ito M, Nakano T. Intraortic pulse pressure is correlated with coronary artery stenosis. *Int Heart J* 2005; **46**: 69-78 [PMID: 15858938 DOI: 10.1536/ihj.46.69]

39 **Safar ME**, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, London GM. Central pulse pressure and mortality in end-stage renal disease. *Hypertension* 2002; **39**: 735-738 [PMID: 11897754 DOI: 10.1161/hy0202.098325]

40 **Pini R**, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, Masotti G, Roman MJ. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. *J Am Coll Cardiol* 2008; **51**: 2432-2439 [PMID: 18565402 DOI: 10.1016/j.jacc.2008.03.031]

41 **Jankowski P**, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badełek M, Wiliński J, Curyło AM, Dudek D. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. *Hypertension* 2008; **51**: 848-855 [PMID: 18268136 DOI: 10.1161/HYPERTENSIONAHA.107.101725]

42 **Asmar RG**, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. *Hypertension* 2001; **38**: 922-926 [PMID: 11641310 DOI: 10.1161/hy1001.095774]

43 . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; **288**: 2981-2997 [PMID: 12479763 DOI: 10.1001/jama.288.23.2981]

44 **Carlberg B**, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? *Lancet* 2004; **364**: 1684-1689 [PMID: 15530629 DOI: 10.1016/S0140-6736(04)17355-8]

45 **Lindholm LH**, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005; **366**: 1545-1553 [PMID: 16257341 DOI: 10.1016/S0140-6736(05)67573-3]

46 . Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. *BMJ* 1992; **304**: 405-412 [PMID: 1445513 DOI: 10.1136/bmj.304.6824.405]

47 **Dahlöf B**, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; **359**: 995-1003 [PMID: 11937178 DOI: 10.1016/S0140-6736(02)08089-3]

48 **Dahlöf B**, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005; **366**: 895-906 [PMID: 16154016 DOI: 10.1016/S0140-6736(05)67185-1]

49 **Grossman E**, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? *JAMA* 1996; **276**: 1328-1331 [PMID: 8861992 DOI: 10.1001/jama.1996.03540160050032]

50 **Schmieder RE**, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. *JAMA* 1996; **275**: 1507-1513 [PMID: 8622227 DOI: 10.1001/jama.1996.03530430051039]

51 **Schiffrin EL**, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. *Hypertension* 1994; **23**: 83-91 [PMID: 8282334 DOI: 10.1161/01.HYP.23.1.83]

52 **Schiffrin EL**, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. *J Hypertens* 1996; **14**: 1247-1255 [PMID: 8906525 DOI: 10.1097/00004872-199610000-00014]

53 **Schiffrin EL**, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. *Circulation* 2000; **101**: 1653-1659 [PMID: 10758046 DOI: 10.1161/01.CIR.101.14.1653]

54 **Safar ME**. Epidemiological findings imply that goals for drug treatment of hypertension need to be revised. *Circulation* 2001; **103**: 1188-1190 [PMID: 11238258 DOI: 10.1161/01.CIR.103.9.1188]

55 **Yu D**, Huang J, Hu D, Chen J, Cao J, Li J, Gu D. Prevalence and risk factors of prehypertension among Chinese adults. *J Cardiovasc Pharmacol* 2008; **52**: 363-368 [PMID: 18841073 DOI: 10.1097/FJC.0b013e31818953ac]

56 **Agyemang C**, van Valkengoed I, van den Born BJ, Stronks K. Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. *Eur J Cardiovasc Prev Rehabil* 2007; **14**: 775-781 [PMID: 18043298 DOI: 10.1097/HJR.0b013e32828621df]

57 **Tsai PS**, Ke TL, Huang CJ, Tsai JC, Chen PL, Wang SY, Shyu YK. Prevalence and determinants of prehypertension status in the Taiwanese general population. *J Hypertens* 2005; **23**: 1355-1360 [PMID: 15942457 DOI: 10.1097/01.hjh.0000173517.68234.c3]

58 **Egan BM**, Julius S. Prehypertension: risk stratification and management considerations. *Curr Hypertens Rep* 2008; **10**: 359-366 [PMID: 18775112 DOI: 10.1007/s11906-008-0068-0]

59 **Agyemang C**, Owusu-Dabo E. Prehypertension in the Ashanti region of Ghana, West Africa: an opportunity for early prevention of clinical hypertension. *Public Health* 2008; **122**: 19-24 [PMID: 17825331 DOI: 10.1016/j.puhe.2007.04.015]

60 **Ganguly SS**, Al-Shafaee MA, Bhargava K, Duttagupta KK. Prevalence of prehypertension and associated cardiovascular risk profiles among prediabetic Omani adults. *BMC Public Health* 2008; **8**: 108 [PMID: 18394173 DOI: 10.1186/1471-2458-8-108]

61 **Janghorbani M**, Amini M, Gouya MM, Delavari A, Alikhani S, Mahdavi A. Nationwide survey of prevalence and risk factors of prehypertension and hypertension in Iranian adults. *J Hypertens* 2008; **26**: 419-426 [PMID: 18300850 DOI: 10.1097/HJH.0b013e3282f2d34d]

62 **Selassie A**, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. *Hypertension* 2011; **58**: 579-587 [PMID: 21911708 DOI: 10.1161/HYPERTENSIONAHA.111.177410]

63 **Liszka HA**, Mainous AG, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. *Ann Fam Med* 2005; **3**: 294-299 [PMID: 16046560 DOI: 10.1370/afm.312]

64 **Lee JH**, Hwang SY, Kim EJ, Kim MJ. Comparison of risk factors between prehypertension and hypertension in Korean male industrial workers. *Public Health Nurs* 2006; **23**: 314-323 [PMID: 16817802 DOI: 10.1111/j.1525-1446.2006.00567.x]

65 **Zhu H**, Yan W, Ge D, Treiber FA, Harshfield GA, Kapuku G, Snieder H, Dong Y. Cardiovascular characteristics in American youth with prehypertension. *Am J Hypertens* 2007; **20**: 1051-1057 [PMID: 17903687 DOI: 10.1016/j.amjhyper.2007.05.009]

66 **Zhang Y**, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, Howard BV. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. *Hypertension* 2006; **47**: 410-414 [PMID: 16446387 DOI: 10.1161/01.HYP.0000205119.19804.08]

67 **Fyhrquist F**, Metsärinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. *J Hum Hypertens* 1995; **9 Suppl 5**: S19-S24 [PMID: 8583476]

68 **Keidar S**, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. *Atherosclerosis* 1995; **115**: 201-215 [PMID: 7661879 DOI: 10.1016/0021-9150(94)05514-J]

69 **Rajagopalan S**, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 1996; **97**: 1916-1923 [PMID: 8621776 DOI: 10.1172/JCI118623]

70 **Münzel T**, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. *J Clin Invest* 1996; **98**: 1465-1470 [PMID: 8823313 DOI: 10.1172/JCI118935]

71 **Cabell KS**, Ma L, Johnson P. Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. *Biochem Pharmacol* 1997; **54**: 133-141 [PMID: 9296359 DOI: 10.1016/S0006-2952(97)00161-5]

72 **Demirci B**, McKeown PP, Bayraktutan U. Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. *J Hypertens* 2005; **23**: 2219-2227 [PMID: 16269964 DOI: 10.1097/01.hjh.0000191906.03983.ee]

73 **Boehm M**, Nabel EG. Angiotensin-converting enzyme 2--a new cardiac regulator. *N Engl J Med* 2002; **347**: 1795-1797 [PMID: 12456857 DOI: 10.1056/NEJMcibr022472]

74 **Crackower MA**, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 2002; **417**: 822-828 [PMID: 12075344 DOI: 10.1038/nature00786]

75 **Kim MA**, Yang D, Kida K, Molotkova N, Yeo SJ, Varki N, Iwata M, Dalton ND, Peterson KL, Siems WE, Walther T, Cowling RT, Kjekshus J, Greenberg B. Effects of ACE2 inhibition in the post-myocardial infarction heart. *J Card Fail* 2010; **16**: 777-785 [PMID: 20797602 DOI: 10.1016/j.cardfail.2010.04.002]

76 **Kalupahana NS**, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. *Obes Rev* 2012; **13**: 136-149 [PMID: 22034852 DOI: 10.1111/j.1467-789X.2011.00942.x]

77 **Pulakat L**, DeMarco VG, Ardhanari S, Chockalingam A, Gul R, Whaley-Connell A, Sowers JR. Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. *Am J Physiol Regul Integr Comp Physiol* 2011; **301**: R885-R895 [PMID: 21813874 DOI: 10.1152/ajpregu.00316.2011]

78 **Ren J**, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. *J Mol Med (Berl)* 2010; **88**: 993-1001 [PMID: 20725711]

79 **Iwai M**, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. *Hypertens Res* 2009; **32**: 533-536 [PMID: 19461648 DOI: 10.1038/hr.2009.74]

80 **Ferrario CM**. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. *Hypertension* 2010; **55**: 445-452 [PMID: 20026757 DOI: 10.1161/HYPERTENSIONAHA.109.145839]

81 **Vašků A**, Bienertová-Vašků J, Pařenica J, Goldbergová MP, Lipková J, Zlámal F, Kala P, Spinar J. ACE2 gene polymorphisms and invasively measured central pulse pressure in cardiac patients indicated for coronarography. *J Renin Angiotensin Aldosterone Syst* 2013; **14**: 220-226 [PMID: 23077079 DOI: 10.1177/1470320312460291]

82 **Montecucco F**, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. *Mediators Inflamm* 2009; **2009**: 752406 [PMID: 19390623 DOI: 10.1155/2009/752406]

83 **Lu H**, Balakrishnan A, Howatt DA, Wu C, Charnigo R, Liau G, Cassis LA, Daugherty A. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. *Br J Pharmacol* 2012; **165**: 2000-2008 [PMID: 22014125 DOI: 10.1111/j.1476-5381.2011.01712.x]

84 **Düsing R**, Brunel P, Baek I, Baschiera F. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study. *J Hypertens* 2012; **30**: 1029-1040 [PMID: 22441345 DOI: 10.1097/HJH.0b013e328351c263]

85 **Fisher ND**, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. *Circulation* 2008; **117**: 3199-3205 [PMID: 18559696 DOI: 10.1161/CIRCULATIONAHA.108.767202]

86 **Lam S**. Azilsartan: a newly approved angiotensin II receptor blocker. *Cardiol Rev* 2011; **19**: 300-304 [PMID: 21983318 DOI: 10.1097/CRD.0b013e31822e9ba3]

87 **Hale TM**, Robertson SJ, Burns KD, deBlois D. Short-term ACE inhibition confers long-term protection against target organ damage. *Hypertens Res* 2012; **35**: 604-610 [PMID: 22318205 DOI: 10.1038/hr.2012.2]

88 **Barodka V**, Silvestry S, Zhao N, Jiao X, Whellan DJ, Diehl J, Sun JZ. Preoperative renin-angiotensin system inhibitors protect renal function in aging patients undergoing cardiac surgery. *J Surg Res* 2011; **167**: e63-e69 [PMID: 20189597 DOI: 10.1016/j.jss.2009.11.702]

89 **Harrap SB**, Davidson HR, Connor JM, Soubrier F, Corvol P, Fraser R, Foy CJ, Watt GC. The angiotensin I converting enzyme gene and predisposition to high blood pressure. *Hypertension* 1993; **21**: 455-460 [PMID: 8384602 DOI: 10.1161/01.HYP.21.4.455]

90 **Tanira MO**, Al Balushi KA. Genetic variations related to hypertension: a review. *J Hum Hypertens* 2005; **19**: 7-19 [PMID: 15361889 DOI: 10.1038/sj.jhh.1001780]

91 **Harrap SB**. Hypertension: genes versus environment. *Lancet* 1994; **344**: 169-171 [PMID: 7912770 DOI: 10.1016/S0140-6736(94)92762-6]

92 **Harrap SB**, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. *Hypertension* 1990; **16**: 603-614 [PMID: 2246027 DOI: 10.1161/01.HYP.16.6.603]

93 **Lundie MJ**, Friberg P, Kline RL, Adams MA. Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. *J Hypertens* 1997; **15**: 339-348 [PMID: 9211168 DOI: 10.1097/00004872-199715040-00004]

94 **Lee RM**, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. *Hypertension* 1991; **17**: 141-150 [PMID: 1991647 DOI: 10.1161/01.HYP.17.2.141]

95 **Unger T**, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. *Hypertension* 1992; **20**: 478-482 [PMID: 1328047 DOI: 10.1161/01.HYP.20.4.478]

96 **Amador N**, Encarnación JJ, Guízar JM, Rodríguez L, López M. Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. *J Hum Hypertens* 2005; **19**: 277-283 [PMID: 15674406 DOI: 10.1038/sj.jhh.1001816]

97 **Baumann M**, Hermans JJ, Janssen BJ, Peutz-Kootstra C, Witzke O, Heemann U, Smits JF, Boudier HA. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. *J Hypertens* 2007; **25**: 2504-2511 [PMID: 17984673 DOI: 10.1097/HJH.0b013e3282ef84f8]

98 **Baumann M**, Janssen BJ, Hermans JJ, Peutz-Kootstra C, Witzke O, Smits JF, Struijker Boudier HA. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. *J Hypertens* 2007; **25**: 207-215 [PMID: 17143193 DOI: 10.1097/HJH.0b013e3280102bff]

99 **Racasan S**, Hahnel B, van der Giezen DM, Blezer EL, Goldschmeding R, Braam B, Kriz W, Koomans HA, Joles JA. Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension. *Kidney Int* 2004; **65**: 575-581 [PMID: 14717927 DOI: 10.1111/j.1523-1755.2004.00410.x]

100 **Cosentino F**, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, Malinski T, Lüscher TF. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. *J Clin Invest* 1998; **101**: 1530-1537 [PMID: 9525996]

101 **Jameson M**, Dai FX, Lüscher T, Skopec J, Diederich A, Diederich D. Endothelium-derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. *Hypertension* 1993; **21**: 280-288 [PMID: 8386699 DOI: 10.1161/01.HYP.21.3.280]

102 **Singh A**, Sventek P, Larivière R, Thibault G, Schiffrin EL. Inducible nitric oxide synthase in vascular smooth muscle cells from prehypertensive spontaneously hypertensive rats. *Am J Hypertens* 1996; **9**: 867-877 [PMID: 8879343 DOI: 10.1016/S0895-7061(96)00104-5]

103 **Gerasimovska-Kitanovska B**, Zafirovska K, Bogdanovska S, Lozance L, Severova-Andreevska G. Decreased nitric oxide in women with essential hypertension in prehypertensive phase. *Croat Med J* 2005; **46**: 889-893 [PMID: 16342341]

104 **Mokuno S**, Ito T, Numaguchi Y, Matsui H, Toki Y, Okumura K, Hayakawa T. Impaired nitric oxide production and enhanced autoregulation of coronary circulation in young spontaneously hypertensive rats at prehypertensive stage. *Hypertens Res* 2001; **24**: 395-401 [PMID: 11510752 DOI: 10.1291/hypres.24.395]

105 **Triggle CR**, Ding H, Anderson TJ, Pannirselvam M. The endothelium in health and disease: a discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. *Mol Cell Biochem* 2004; **263**: 21-27 [PMID: 15524164 DOI: 10.1023/B: MCBI.0000041845.62061.c9]

106 **Giannotti G**, Doerries C, Mocharla PS, Mueller MF, Bahlmann FH, Horvàth T, Jiang H, Sorrentino SA, Steenken N, Manes C, Marzilli M, Rudolph KL, Lüscher TF, Drexler H, Landmesser U. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. *Hypertension* 2010; **55**: 1389-1397 [PMID: 20458006 DOI: 10.1161/HYPERTENSIONAHA.109.141614]

107 **McCarron DA**, Morris CD, Henry HJ, Stanton JL. Blood pressure and nutrient intake in the United States. *Science* 1984; **224**: 1392-1398 [PMID: 6729459 DOI: 10.1126/science.6729459]

108 **Salonen JT**, Salonen R, Ihanainen M, Parviainen M, Seppänen R, Kantola M, Seppänen K, Rauramaa R. Blood pressure, dietary fats, and antioxidants. *Am J Clin Nutr* 1988; **48**: 1226-1232 [PMID: 3189209 DOI: 10.3109/07853899109148063]

109 **Yoshioka M**, Matsushita T, Chuman Y. Inverse association of serum ascorbic acid level and blood pressure or rate of hypertension in male adults aged 30-39 years. *Int J Vitam Nutr Res* 1984; **54**: 343-347 [PMID: 6151942]

110 **Nabha L**, Garbern JC, Buller CL, Charpie JR. Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. *Clin Exp Hypertens* 2005; **27**: 71-82 [PMID: 15773231 DOI: 10.1081/CEH-200044267]

111 **Witztum JL**. The oxidation hypothesis of atherosclerosis. *Lancet* 1994; **344**: 793-795 [PMID: 7916078 DOI: 10.1016/S0140-6736(94)92346-9]

112 **Offermann MK**, Medford RM. Antioxidants and atherosclerosis: a molecular perspective. *Heart Dis Stroke* 1994; **3**: 52-57 [PMID: 7511030]

113 **Kunsch C**, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. *Circ Res* 1999; **85**: 753-766 [PMID: 10521248 DOI: 10.1161/01.RES.85.8.753]

114 **Nambiar S**, Viswanathan S, Zachariah B, Hanumanthappa N, Magadi SG. Oxidative stress in prehypertension: rationale for antioxidant clinical trials. *Angiology* 2009; **60**: 221-234 [PMID: 18796443 DOI: 10.1177/0003319708319781]

115 **Boos CJ**, Lip GY. Is hypertension an inflammatory process? *Curr Pharm Des* 2006; **12**: 1623-1635 [PMID: 16729874 DOI: 10.2174/138161206776843313]

116 **Chrysohoou C**, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. *Am J Hypertens* 2004; **17**: 568-573 [PMID: 15233975 DOI: 10.1016/j.amjhyper.2004.03.675]

117 **Pitsavos C**, Chrysohoou C, Panagiotakos DB, Lentzas Y, Stefanadis C. Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women: the ATTICA Study. *Heart Vessels* 2008; **23**: 96-103 [PMID: 18389333 DOI: 10.1007/s00380-007-1018-5]

118 **Kogure M**, Ichikawa S, Yagi S, Sato K, Fujita H, Fujie M, Kumakura H, Yagi A, Nakamura T, Murata K. Prostaglandins in enhanced pressor response in renal prehypertensive rabbits. *Life Sci* 1987; **40**: 1277-1286 [PMID: 3550345 DOI: 10.1016/0024-3205(87)90584-4]

119 **Eyal S**, Oz O, Eliash S, Wasserman G, Akselrod S. The diastolic decay constant in spontaneously hypertensive rats versus WKY rats as an indicator for vasomotor control. *J Auton Nerv Syst* 1997; **64**: 24-32 [PMID: 9188082 DOI: 10.1016/S0165-1838(97)00012-X]

120 **Fujimoto S**, Dohi Y, Aoki K, Asano M, Matsuda T. Diminished beta-adrenoceptor-mediated relaxation of arteries from spontaneously hypertensive rats before and during development of hypertension. *Eur J Pharmacol* 1987; **136**: 179-187 [PMID: 3036546 DOI: 10.1016/0014-2999(87)90710-2]

121 **Goto K**, Fujii K, Abe I. Impaired beta-adrenergic hyperpolarization in arteries from prehypertensive spontaneously hypertensive rats. *Hypertension* 2001; **37**: 609-613 [PMID: 11230343 DOI: 10.1161/01.HYP.37.2.609]

122 **Fujimoto S**, Matsuda T. M3 cholinoceptors and P2y purinoceptors mediating relaxation of arteries in spontaneously hypertensive rats at prehypertensive stages. *Eur J Pharmacol* 1991; **202**: 9-15 [PMID: 1786803 DOI: 10.1016/0014-2999(91)90247-N]

123 **Schiffrin EL**, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. *Am J Hypertens* 1995; **8**: 229-236 [PMID: 7794571 DOI: 10.1016/0895-7061(95)96211-2]

124 **Schiffrin EL**, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. *Hypertension* 1995; **25**: 699-703 [PMID: 7721419 DOI: 10.1161/01.HYP.25.4.699]

125 **Galloway MP**, Westfall TC. The release of endogenous norepinephrine from the coccygeal artery of spontaneously hypertensive and Wistar-Kyoto rats. *Circ Res* 1982; **51**: 225-232 [PMID: 7094231 DOI: 10.1161/01.RES.51.2.225]

126 **Misu Y**, Kuwahara M, Kubo T. Some relevance of presynaptic beta-adrenoceptors to development of hypertension in spontaneously hypertensive rats. *Arch Int Pharmacodyn Ther* 1987; **287**: 299-308 [PMID: 2820328]

127 **Tsuji T**, Su C, Lee TJ. Enhanced presynaptic beta 2-adrenoceptor-mediated facilitation of the pressor responses in the prehypertensive SHR. *J Cardiovasc Pharmacol* 1989; **14**: 737-746 [PMID: 2481188 DOI: 10.1097/00005344-198911000-00010]

128 **Gordon FJ**, Mark AL. Impaired baroreflex control of vascular resistance in prehypertensive Dahl S rats. *Am J Physiol* 1983; **245**: H210-H217 [PMID: 6881355]

129 **Gordon FJ**, Mark AL. Mechanism of impaired baroreflex control in prehypertensive Dahl salt-sensitive rats. *Circ Res* 1984; **54**: 378-387 [PMID: 6713604 DOI: 10.1161/01.RES.54.4.378]

130 **Kotchen TA**, Guthrie GP, McKean H, Kotchen JM. Adrenergic responsiveness in prehypertensive subjects. *Circulation* 1982; **65**: 285-290 [PMID: 7032747 DOI: 10.1161/01.CIR.65.2.285]

131 **Kotchen TA**, Kotchen JM, Guthrie GP, Berk MR, Knapp CF, McFadden M. Baroreceptor sensitivity in prehypertensive young adults. *Hypertension* 1989; **13**: 878-883 [PMID: 2737725 DOI: 10.1161/01.HYP.13.6.878]

132 **Kubo T**, Hagiwara Y. Activities of hypothalamic angiotensin II-sensitive neurons are greately enhanced even in prehypertensive spontaneously hypertensive rats. *Neurosci Lett* 2006; **397**: 74-78 [PMID: 16384641 DOI: 10.1016/j.neulet.2005.11.059]

133 **Nakamura Y**, Takeda K, Nakata T, Hayashi J, Kawasaki S, Lee LC, Sasaki S, Nakagawa M, Ijichi H. Central attenuation of aortic baroreceptor reflex in prehypertensive DOCA-salt-loaded rats. *Hypertension* 1988; **12**: 259-266 [PMID: 3169941 DOI: 10.1161/01.HYP.12.3.259]

134 **Brown-Maher T**. Multidisciplinary approach to chronic wound care: our 2-year Newfoundland and Labrador experience. *J Cutan Med Surg* 2009; **13 Suppl 1**: S26-S28 [PMID: 19480748]

135 **Scheen AJ**. [Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"]. *Rev Med Liege* 1999; **54**: 197-199 [PMID: 10321112]

136 **De Marco M**, de Simone G, Roman MJ, Chinali M, Lee ET, Russell M, Howard BV, Devereux RB. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. *Hypertension* 2009; **54**: 974-980 [PMID: 19720957 DOI: 10.1161/HYPERTENSIONAHA.109.129031]

137 **Izzo JL**. Prehypertension: demographics, pathophysiology, and treatment. *Curr Hypertens Rep* 2007; **9**: 264-268 [PMID: 17686375 DOI: 10.1007/s11906-007-0049-8]

138 **Izzo JL**, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. *Hypertension* 2000; **35**: 1021-1024 [PMID: 10818056 DOI: 10.1161/01.HYP.35.5.1021]

139 **Qureshi AI**, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? *Stroke* 2005; **36**: 1859-1863 [PMID: 16081866 DOI: 10.1161/01.STR.0000177495.45580.f1]

140 **Lloyd-Jones DM**, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation* 2006; **113**: 791-798 [PMID: 16461820 DOI: 10.1161/CIRCULATIONAHA.105.548206]

141 **Naiman A**, Glazier RH, Moineddin R. Association of anti-smoking legislation with rates of hospital admission for cardiovascular and respiratory conditions. *CMAJ* 2010; **182**: 761-767 [PMID: 20385737 DOI: 10.1503/cmaj.091130]

142 **Callinan JE**, Clarke A, Doherty K, Kelleher C. Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. *Cochrane Database Syst Rev* 2010; : CD005992 [PMID: 20393945 DOI: 10.1002/14651858.CD005992.pub2]

143 **Vartiainen E**, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol* 2010; **39**: 504-518 [PMID: 19959603 DOI: 10.1093/ije/dyp330]

144 **Weinehall L**, Hellsten G, Boman K, Hallmans G, Asplund K, Wall S. Can a sustainable community intervention reduce the health gap?--10-year evaluation of a Swedish community intervention program for the prevention of cardiovascular disease. *Scand J Public Health Suppl* 2001; **56**: 59-68 [PMID: 11681565 DOI: 10.1177/14034948010290021901]

145 . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. *Arch Intern Med* 1997; **157**: 657-667 [PMID: 9080920 DOI: 10.1001/archinte.1997.00440270105009]

146 . The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Hypertension Prevention Trial Research Group. *Arch Intern Med* 1990; **150**: 153-162 [PMID: 2404477 DOI: 10.1001/archinte.1990.00390130131021]

147 **Stevens VJ**, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, Mattfeldt-Beman M, Oberman A, Sugars C, Dalcin AT. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. *Arch Intern Med* 1993; **153**: 849-858 [PMID: 8466377 DOI: 10.1001/archinte.153.7.849]

148 **Neter JE**, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2003; **42**: 878-884 [PMID: 12975389 DOI: 10.1161/01.HYP.0000094221.86888.AE]

149 **Elmer PJ**, Grimm R, Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). *Prev Med* 1995; **24**: 378-388 [PMID: 7479629 DOI: 10.1006/pmed.1995.1062]

150 **Appel LJ**, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med* 1997; **336**: 1117-1124 [PMID: 9099655 DOI: 10.1056/NEJM199704173361601]

151 http: //www.nhlbi.nih.gov/health/public/heart/hbp/dash/new\_dash.pdf (accessed November 2, 2013)

152 **Sacks FM**, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med* 2001; **344**: 3-10 [PMID: 11136953 DOI: 10.1056/NEJM200101043440101]

153 **Appel LJ**, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. *JAMA* 2005; **294**: 2455-2464 [PMID: 16287956 DOI: 10.1001/jama.294.19.2455]

154 **Collier SR**, Frechette V, Sandberg K, Schafer P, Ji H, Smulyan H, Fernhall B. Sex differences in resting hemodynamics and arterial stiffness following 4 weeks of resistance versus aerobic exercise training in individuals with pre-hypertension to stage 1 hypertension. *Biol Sex Differ* 2011; **2**: 9 [PMID: 21867499 DOI: 10.1186/2042-6410-2-9]

155 **Collier SR**, Kanaley JA, Carhart R, Frechette V, Tobin MM, Hall AK, Luckenbaugh AN, Fernhall B. Effect of 4 weeks of aerobic or resistance exercise training on arterial stiffness, blood flow and blood pressure in pre- and stage-1 hypertensives. *J Hum Hypertens* 2008; **22**: 678-686 [PMID: 18432253 DOI: 10.1038/jhh.2008.36]

156 **Jennings G**, Nelson L, Nestel P, Esler M, Korner P, Burton D, Bazelmans J. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. *Circulation* 1986; **73**: 30-40 [PMID: 3510088 DOI: 10.1161/01.CIR.73.1.30]

157 **Neaton JD**, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. *JAMA* 1993; **270**: 713-724 [PMID: 8336373 DOI: 10.1001/jama.1993.03510240036015]

158 **Braith RW**, Pollock ML, Lowenthal DT, Graves JE, Limacher MC. Moderate- and high-intensity exercise lowers blood pressure in normotensive subjects 60 to 79 years of age. *Am J Cardiol* 1994; **73**: 1124-1128 [PMID: 8198040 DOI: 10.1016/0002-9149(94)90294-1]

159 **Román O**, Camuzzi AL, Villalón E, Klenner C. Physical training program in arterial hypertension. A long-term prospective follow-up. *Cardiology* 1981; **67**: 230-243 [PMID: 7248998 DOI: 10.1159/000173248]

160 **Blumenthal JA**, Siegel WC, Appelbaum M. Failure of exercise to reduce blood pressure in patients with mild hypertension. Results of a randomized controlled trial. *JAMA* 1991; **266**: 2098-2104 [PMID: 1920698 DOI: 10.1001/jama.1991.03470150070033]

161 **Kelley GA**, Kelley KS. Progressive resistance exercise and resting blood pressure : A meta-analysis of randomized controlled trials. *Hypertension* 2000; **35**: 838-843 [PMID: 10720604 DOI: 10.1161/01.HYP.35.3.838]

162 **Whelton SP**, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med* 2002; **136**: 493-503 [PMID: 11926784 DOI: 10.7326/0003-4819-136-7-200204020-00006]

163 **Taylor RS**, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. *Am J Med* 2004; **116**: 682-692 [PMID: 15121495 DOI: 10.1016/j.amjmed.2004.01.009]

164 **Thompson PD**, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation* 2003; **107**: 3109-3116 [PMID: 12821592 DOI: 10.1161/01.CIR.0000075572.40158.77]

165 **Turnbull F**. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 2003; **362**: 1527-1535 [PMID: 14615107 DOI: 10.1016/S0140-6736(03)14739-3]

166 **Wilt TJ**, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A. Effectiveness of statin therapy in adults with coronary heart disease. *Arch Intern Med* 2004; **164**: 1427-1436 [PMID: 15249352 DOI: 10.1001/archinte.164.13.1427]

167 **Hedayati SS**, Elsayed EF, Reilly RF. Non-pharmacological aspects of blood pressure management: what are the data? *Kidney Int* 2011; **79**: 1061-1070 [PMID: 21389976 DOI: 10.1038/ki.2011.46]

168 **Ebrahim S**, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. *Cochrane Database Syst Rev* 2006; : CD001561 [PMID: 17054138 DOI: 10.1002/14651858.CD001561.pub2]

169 **Appel LJ**, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA* 2003; **289**: 2083-2093 [PMID: 12709466 DOI: 10.1001/jama.289.16.2083]

170 **Vartiainen E**, Puska P, Jousilahti P, Korhonen HJ, Tuomilehto J, Nissinen A. Twenty-year trends in coronary risk factors in north Karelia and in other areas of Finland. *Int J Epidemiol* 1994; **23**: 495-504 [PMID: 7960373 DOI: 10.1093/ije/23.3.495]

171 **Watson AJ**, Singh K, Myint-U K, Grant RW, Jethwani K, Murachver E, Harris K, Lee TH, Kvedar JC. Evaluating a web-based self-management program for employees with hypertension and prehypertension: a randomized clinical trial. *Am Heart J* 2012; **164**: 625-631 [PMID: 23067923 DOI: 10.1016/j.ahj.2012.06.013]

172 **Riegel G**, Moreira LB, Fuchs SC, Gus M, Nunes G, Correa V, Wiehe M, Gonçalves CC, Fernandes FS, Fuchs FD. Long-term effectiveness of non-drug recommendations to treat hypertension in a clinical setting. *Am J Hypertens* 2012; **25**: 1202-1208 [PMID: 22810842 DOI: 10.1038/ajh.2012.103.Epub]

173 **Puddey IB**, Beilin LJ, Vandongen R, Rouse IL, Rogers P. Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men. A randomized controlled trial. *Hypertension* 1985; **7**: 707-713 [PMID: 3897044 DOI: 10.1161/01.HYP.7.5.707]

174 **Cushman WC**, Cutler JA, Hanna E, Bingham SF, Follmann D, Harford T, Dubbert P, Allender PS, Dufour M, Collins JF, Walsh SM, Kirk GF, Burg M, Felicetta JV, Hamilton BP, Katz LA, Perry HM, Willenbring ML, Lakshman R, Hamburger RJ. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. *Arch Intern Med* 1998; **158**: 1197-1207 [PMID: 9625399 DOI: 10.1001/archinte.158.11.1197]

175 **Xin X**, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2001; **38**: 1112-1117 [PMID: 11711507 DOI: 10.1161/hy1101.093424]

176 **Fuchs FD**, Fuchs SC, Moreira LB, Gus M, Nóbrega AC, Poli-de-Figueiredo CE, Mion D, Bortoloto L, Consolim-Colombo F, Nobre F, Coelho EB, Vilela-Martin JF, Moreno H, Cesarino EJ, Franco R, Brandão AA, de Sousa MR, Ribeiro AL, Jardim PC, Neto AA, Scala LC, Mota M, Chaves H, Alves JG, Filho DC, Pereira e Silva R, Neto JA, Irigoyen MC, Castro I, Steffens AA, Schlatter R, de Mello RB, Mosele F, Ghizzoni F, Berwanger O. Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.*Trials* 2011; **12**: 65 [PMID: 21375762 DOI: 10.1186/1745-6215-12-65]

177 http: //www.medscape.com/viewarticle/778740 Accessed November 2, 2013

178 **Julius S**, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, Michelson E. Trial of preventing hypertension: design and 2-year progress report. *Hypertension* 2004; **44**: 146-151 [PMID: 15238567 DOI: 10.1161/01.HYP.0000130174.70055.ca]

179 **Julius S**, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med* 2006; **354**: 1685-1697 [PMID: 16537662 DOI: 10.1056/NEJMoa060838]

180 **Hart MN**, Heistad DD, Brody MJ. Effect of chronic hypertension and sympathetic denervation on wall/lumen ratio of cerebral vessels. *Hypertension* 1980; **2**: 419-423 [PMID: 7399625 DOI: 10.1161/01.HYP.2.4.419]

181 **Dzau V**. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. *J Hypertens Suppl* 2005; **23**: S9-17 [PMID: 15821452 DOI: 10.1097/01.hjh.0000165623.72310.dd]

182 **Qureshi AI**, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. *Med Sci Monit* 2005; **11**: CR403-CR409 [PMID: 16127357]

183 **Lüders S**, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. *J Hypertens* 2008; **26**: 1487-1496 [PMID: 18551027 DOI: 10.1097/HJH.0b013e3282ff8864]

184 **Pimenta E**, Oparil S. Prehypertension: epidemiology, consequences and treatment. *Nat Rev Nephrol* 2010; **6**: 21-30 [PMID: 19918256 DOI: 10.1038/nrneph.2009.191]

185 **Staessen JA**, Richart T, Wang Z, Thijs L. Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. *Hypertension* 2010; **55**: 819-831 [PMID: 20212274 DOI: 10.1161/HYPERTENSIONAHA.108.122879]

186 **Nicholls SJ**, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. *JAMA* 2013; **310**: 1135-1144 [PMID: 23999933 DOI: 10.1001/jama.2013.277169]

187 **Ford ES**, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med* 2007; **356**: 2388-2398 [PMID: 17554120 DOI: 10.1056/NEJMsa053935]

188 World Health Statistics 2009. Table 2: cause-specific mortality and morbidity. Available at: http: //www.who.int/whosis/whostat/EN\_WHS09\_Table2.pdf Accessed July 2, 2010

189 **Yusuf S**, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; **364**: 937-952 [PMID: 15364185 DOI: 10.1016/S0140-6736(04)17018-9]

190 **O'Donnell MJ**, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010; **376**: 112-123 [PMID: 20561675 DOI: 0.1016/S0140-6736(10)60834-3]

191 **Ford ES**, Li C, Zhao G, Pearson WS, Capewell S. Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults. *Circulation* 2009; **120**: 1181-1188 [PMID: 19752328 DOI: 10.1161/CIRCULATIONAHA.108.835728]

192 **Ventura HO**, Lavie CJ. Antihypertensive therapy for prehypertension: relationship with cardiovascular outcomes. *JAMA* 2011; **305**: 940-941 [PMID: 21364146 DOI: 10.1001/jama.2011.256]

193 **Rodgers A**, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, Jackson R, Neal B, Neaton J, Poulter N, Rafter N, Raju PK, Reddy S, Thom S, Vander Hoorn S, Webster R. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. *PLoS One* 2011; **6**: e19857 [PMID: 21647425 DOI: 10.1371/journal.pone.0019857]

194 **Wald DS**, Morris JK, Wald NJ. Randomized Polypill crossover trial in people aged 50 and over. *PLoS One* 2012; **7**: e41297 [PMID: 22815989 DOI: 10.1371/journal.pone.0041297]

195 **Parati G**, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. *Nat Rev Cardiol* 2013; **10**: 143-155 [PMID: 23399972 DOI: 10.1038/nrcardio.2013.1]

196 **Burt VL**, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension* 1995; **25**: 305-313 [PMID: 7875754 DOI: 10.1161/01.HYP.25.3.305]

197 **Sandberg K**, Ji H. Sex differences in primary hypertension. *Biol Sex Differ* 2012; **3**: 7 [PMID: 22417477 DOI: 10.1186/2042-6410-3-7]

198 **Chen X**, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. *Circulation* 2008; **117**: 3171-3180 [PMID: 18559702 DOI: 10.1161/CIRCULATIONAHA.107.730366]

199 **Wang Y**, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. *Arch Intern Med* 2004; **164**: 2126-2134 [PMID: 15505126 DOI: 10.1001/archinte.164.19.2126]

200 **Cummings DM**, Letter AJ, Howard G, Howard VJ, Safford MM, Prince V, Muntner P. Generic medications and blood pressure control in diabetic hypertensive subjects: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. *Diabetes Care* 2013; **36**: 591-597 [PMID: 23150284 DOI: 10.2337/dc12-0755]

201 **Pavlik VN**, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). *Neuroepidemiology* 2005; **24**: 42-50 [PMID: 15459509 DOI: 10.1159/000081049]

202 **Glasser SP**, Judd S, Basile J, Lackland D, Halanych J, Cushman M, Prineas R, Howard V, Howard G. Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. *Am J Hypertens* 2011; **24**: 194-199 [PMID: 20864944 DOI: 10.1038/ajh.2010.204]

203 **Svetkey LP**. Management of prehypertension. *Hypertension* 2005; **45**: 1056-1061 [PMID: 15897368 DOI: 10.1161/01.HYP.0000167152.98618.4b]

**P-Reviewer:** Jankowski P  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**